SARS-CoV-2 vaccines effectively prevent infection in VA population
Jul 20, 2021
Vaccine effectiveness was 96.2% for Pfizer-BioNTech BNT162b2 and 98.2% for Moderna mRNA-1273.
mRNA COVID-19 vaccine effectiveness lower during delta strain era
Aug 20, 2021
Adjusted effectiveness was 53.1% against infection in nursing home residents during the period when delta strain was predominant.
SARS-CoV-2 vaccine effectiveness 66 percent during delta predominance
Aug 25, 2021
Vaccine effectiveness for all three vaccines decreased from 91% in the months preceding delta predominance.
Vaccination protects against death from SARS-CoV-2 delta variant
Oct 28, 2021
A Scotland cohort study shows that vaccination effectiveness with the ChAdOx1 nCoV-19 (Astra Zeneca, not available in the U.S.) or BNT162b2 (Pfizer–BioNTech) vaccine was 90% and 87%, respectively, for...
Odds of SARS-CoV-2 infection down after third BNT162b2 dose
Dec 03, 2021
The estimated odds ratio of 0.14 at 28 to 65 days after receipt of the Pfizer-BioNTech booster was compared with those who received two doses.
Third BNT162b2 vaccine dose may cut severe COVID-19 outcomes
Nov 05, 2021
Fewer hospital admissions, cases of severe disease and COVID-19-related deaths were seen with the third dose of the Pfizer-BioNTech vaccine versus two doses received five months ago.
Allergy history may up risk for reactions to mRNA COVID-19 vaccine
Nov 04, 2021
The risk for allergic reactions within three days of vaccination is higher for those with history of high-risk allergy, but most completed the two-dose regimen. The mRNA vaccines approved for use against...
For fully vaccinated, immunity against SARS-CoV-2 wanes over time
Oct 29, 2021
The researchers found that among persons aged 60 years or older, the rate of infection was higher for those fully vaccinated in January 2021 (when they were first eligible) versus those fully vaccinated...
Booster dose of J&J COVID-19 vaccine may increase immunity
Sep 21, 2021
New research indicates two doses of the vaccine boosts immunity from 74 to 94%.
Second, third COVID-19 vaccine may up relapse in glomerular disease
Nov 07, 2022
The absolute increase in the 30-day relapse risk associated with the second or third vaccine dose is small.